473 filings
PRE 14A
VTGN
VistaGen Therapeutics Inc
Preliminary proxy
31 Dec 20
5:21pm
8-K
VTGN
VistaGen Therapeutics Inc
22 Dec 20
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
4:17pm
424B5
VTGN
VistaGen Therapeutics Inc
21 Dec 20
Prospectus supplement for primary offering
12:00am
FWP
VTGN
VistaGen Therapeutics Inc
18 Dec 20
Free writing prospectus
6:38am
424B5
VTGN
VistaGen Therapeutics Inc
17 Dec 20
Prospectus supplement for primary offering
5:13pm
8-K
euh585ni6 ep2huyzk
1 Dec 20
Other Events
4:24pm
8-K
pzg44van8q 0gipaq
16 Nov 20
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
12:00am
8-K
pcwplw
13 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:06pm
SC 13G
rle 1izs9wj
18 Sep 20
VistaGen Therapeutics / Rosalind Advisors ownership change
4:56pm
8-K
u12uhtt276h7an x3j0b
18 Sep 20
2020 Virtual Annual Meeting of Stockholders
9:14am
4
ounh1d3a3dculr mo3
24 Aug 20
VistaGen Therapeutics / JON S SAXE ownership change
4:31pm
8-K
9wtl4jh7gg91n 8aha
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
8-K
hotn2wcw95iha 3483r
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
424B5
mivb8 odw3me1k1
3 Aug 20
Prospectus supplement for primary offering
8:45pm
424B5
mum4hi
31 Jul 20
Prospectus supplement for primary offering
4:16pm
DEFA14A
jtgo9udts kqpr
27 Jul 20
Additional proxy soliciting materials
4:52pm
8-K
22r022esi
24 Jul 20
Regulation FD Disclosure
6:03am